{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:13Z","timestamp":1790995153229,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ahj.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:43:46Z","timestamp":1748259826000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran\u2019s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia"],"prefix":"10.1016","volume":"289","author":[{"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim B.","family":"Winzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lubyayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hendrik","family":"Streich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hentschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assya","family":"Achouba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.05.014_bib0001","unstructured":"Deaths from cardiovascular disease surged 60% globally over the last 30 years: report\u2014World Heart Federation 2024 [Available from: https:\/\/world-heart-federation.org\/news\/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report\/. [Accessed 11 June 2025]."},{"key":"10.1016\/j.ahj.2025.05.014_bib0002","unstructured":"Cardiovascular diseases (CVDs) 2021 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)?gad_source=1&gclid=EAIaIQobChMIo7qlyMTBhwMVMaRmAh1HPzv2EAAYASAAEgKKEPD_BwE. [Accessed 11 June, 2025]."},{"issue":"25","key":"10.1016\/j.ahj.2025.05.014_bib0003","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular D, risks C. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.05.014_bib0004","unstructured":"DE Bloom, et al. The Global economic Burden of noncommunicable diseases 2011. Available from WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf [Accessed 11 June 2025]."},{"issue":"38","key":"10.1016\/j.ahj.2025.05.014_bib0005","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1093\/eurheartj\/ehae466","article-title":"European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics","volume":"45","author":"Timmis","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.05.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100222","article-title":"Association of health-related quality of life with atherosclerotic cardiovascular disease: lifetime risk pooling project","volume":"7","author":"Ning","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"17","key":"10.1016\/j.ahj.2025.05.014_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175231","article-title":"Health-related quality of life (HRQoL) and the effect on outcome in patients presenting with coronary artery disease and treated with percutaneous coronary intervention (PCI): differences noted by sex and age","volume":"11","author":"Conradie","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ahj.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12889-021-11348-w","article-title":"Trend analysis of disability adjusted life years due to cardiovascular diseases: results from the global burden of disease study 2019","volume":"21","author":"Masaebi","year":"2021","journal-title":"BMC Public Health"},{"issue":"27","key":"10.1016\/j.ahj.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"32","key":"10.1016\/j.ahj.2025.05.014_bib0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.05.014_bib0012","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"10.1016\/j.ahj.2025.05.014_bib0013","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"10.1016\/j.ahj.2025.05.014_bib0014","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.ahj.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2025.05.014_bib0016","doi-asserted-by":"crossref","first-page":"70-9 e1","DOI":"10.1016\/j.jacl.2016.10.003","article-title":"Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system","volume":"11","author":"Graham","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ahj.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"17","key":"10.1016\/j.ahj.2025.05.014_bib0018","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"oeac071","DOI":"10.1093\/ehjopen\/oeac071","article-title":"Adherence to statin therapy: it seems we know everything, yet we do nothing","volume":"2","author":"Banach","year":"2022","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.ahj.2025.05.014_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2025.05.014_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.ahj.2025.05.014_bib0022","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ahj.2025.05.014_bib0023","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacl.2019.04.011","article-title":"The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy","volume":"13","author":"Jacobson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ahj.2025.05.014_bib0024","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/clc.22975","article-title":"Understanding patient Adherence and concerns with STatins and MedicatION discussions with physicians (ACTION): a survey on the patient perspective of dialogue with healthcare providers regarding statin therapy","volume":"41","author":"Brinton","year":"2018","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2025.05.014_bib0025","first-page":"685","article-title":"Patterns of Statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.ahj.2025.05.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"10.1016\/j.ahj.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"Akyea","year":"2019","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.ahj.2025.05.014_bib0028","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.05.014_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position Paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ahj.2025.05.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 Recommendations on the optimal use of Lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP)","author":"Banach","year":"2024","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.ahj.2025.05.014_bib0031","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2025.05.014_bib0032","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/10600280221105169","article-title":"Inclisiran: a first-in-class siRNA therapy for lowering low-density lipoprotein cholesterol","volume":"57","author":"Samuel","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"24","key":"10.1016\/j.ahj.2025.05.014_bib0033","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2025.05.014_bib0034","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"25","key":"10.1016\/j.ahj.2025.05.014_bib0035","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ahj.2025.05.014_bib0036","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.ahj.2025.05.014_bib0037","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.ahj.2025.05.014_bib0038","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.05.014_bib0039","unstructured":"Prescribing information Leqvio 2021 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214012lbl.pdf. [Accessed 11 June 2025]."},{"issue":"4","key":"10.1016\/j.ahj.2025.05.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100894","article-title":"Individualized dose-response to statins associated with cardiovascular disease outcomes","volume":"3","author":"Aggarwal","year":"2024","journal-title":"JACC Adv"},{"issue":"2","key":"10.1016\/j.ahj.2025.05.014_bib0041","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res."},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2025.05.014_bib0042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000176762","article-title":"Hypertension\u2014hen is the clinical problem solved? When quality of life is secured","volume":"85","author":"Ware","year":"1994","journal-title":"Cardiology"},{"issue":"13","key":"10.1016\/j.ahj.2025.05.014_bib0043","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJM199603283341306","article-title":"Assessment of quality-of-life outcomes","volume":"334","author":"Testa","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2025.05.014_bib0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpain.2004.09.006","article-title":"Further validation of the chronic pain coping inventory","volume":"6","author":"Tan","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.ahj.2025.05.014_bib0045","unstructured":"CS Cleeland. The brief pain inventory user guide 2009. Available on: https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf. [Accessed 11 June 2025]."},{"issue":"5","key":"10.1016\/j.ahj.2025.05.014_bib0046","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin J Pain"},{"issue":"12","key":"10.1016\/j.ahj.2025.05.014_bib0047","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/pm\/pnaa269","article-title":"Brief pain inventory-short form: a new method for assessing pain in the Emergency department","volume":"21","author":"Im","year":"2020","journal-title":"Pain Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325001796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:56:32Z","timestamp":1767761792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325001796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0002870325001796"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.05.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran\u2019s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}